The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is cont...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes therapy 2022-05, Vol.13 (5), p.847-872
Hauptverfasser:	Wilding, John P. H., Evans, Marc, Fernando, Kevin, Gorriz, Jose Luis, Cebrian, Ana, Diggle, Jane, Hicks, Debbie, James, June, Newland-Jones, Philip, Ali, Amar, Bain, Stephen, Da Porto, Andrea, Patel, Dipesh, Viljoen, Adie, Wheeler, David C., Del Prato, Stefano
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Complications and side effects Coronaviruses COVID-19 Diabetes Drug therapy Drugs Economic aspects Endocrinology Glucose Hyperglycemia Hypoglycemic agents Internal Medicine Medicine Medicine & Public Health Pandemics Prescribing Review Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!